Dec 10, 2019 / 06:30AM GMT
Kenji Yasukawa - Astellas Pharma Inc. - President, CEO & Representative Director
[Interpreted] Once again, good afternoon. I'm Yasukawa. We had the financial result meeting the other day. As I promised before, today we'd like to talk about Astellas immuno-oncology strategy, our pipeline and also the capabilities and the progress as well. Ogata already read the disclaimer, so I'd like to skip this page.
Next, Page 3. This is the agenda today. First of all, I will talk about the R&D history, why Astellas decided to work on immuno-oncology and also the Astellas immuno-oncology strategy. And Primary Focus Lead, Peter Sandor, will explain the details of the immuno-oncology strategy and Steven Benner, Development President, will explain the clinical pipeline in immuno-oncology in detail.
Next page, please. In 2018, we announced our corporate strategic plan, as was mentioned there, Astellas decided to use Focus Area approach to create innovative drugs for diseases with unmet medical needs. That was what we declared. In other words, using the biology as a fundamental for the diseases. In
Astellas Pharma Inc Approaches to Immuno-Oncology R&D Conference Call Transcript
Feb 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers